p53 immunoreactivity is uncommon in primary cutaneous lymphoma.
p53 gene mutation appears to play an important role in the development of systemic lymphoma, and may be associated with tumour progression. Its role in cutaneous lymphoma is currently unknown. We examined p53 expression in 55 biopsies of cutaneous lymphoma, including patch-, plaque- and tumour-stage mycosis fungoides (MF), T- and B-cell lymphoma and lymphomatoid papulosis. Strong, homogeneous p53 expression, thought to correlate most closely with p53 gene mutation, was seen in only three cases; in a plaque and tumour from a patient with tumour-stage MF, in plaque-stage MF in a patient without tumours, and in one case of CD30+ large-cell anaplastic lymphoma. These data suggest that p53 gene mutation is not a critical step in the development of the majority of primary cutaneous lymphomas.
McGregor
J M
JM
Department of Dermatology, UMDS (Guy's Campus), London, U.K.
Dublin
E A
EA
Levison
D A
DA
MacDonald
D M
DM
Smith
N P
NP
Whittaker
S
S
D006801:Humans; D007150:Immunohistochemistry; D008223:Lymphoma / Q000378:metabolism*; D016393:Lymphoma, B-Cell / Q000378:metabolism; D016410:Lymphoma, T-Cell, Cutaneous / Q000378:metabolism; D009182:Mycosis Fungoides / Q000378:metabolism; D012878:Skin Neoplasms / Q000378:metabolism*; D016159:Tumor Suppressor Protein p53 / Q000096:biosynthesis*
D016159:Tumor Suppressor Protein p53